Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
Trial Parameters
Brief Summary
To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.
Eligibility Criteria
Inclusion Criteria: * Patient is 18-75 years old at the time of signing the informed consent form. * ECOG performance status 0-1. * Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum. * Distant metastasis lesions are no more than 10 and all sites of disease can be safely treated based on a pre-plan. * At least one evaluable metastatic lesion for radiotherapy and evaluation according to RECIST 1.1. * No prior radiotherapy within 6 month. * Previous system therapy. Patients Group Cohort A: participants who have not previously been treated with first-line chemotherapy. Cohort B: Patients with disease progression after first-line chemotherapy or stopped first-line therapy due to unacceptable toxic effects . * Has an investigator determined life expectancy of at least 24 weeks. * Demonstrate adequate organ function (bone marrow, liver, kidney and clotting function) within 7 days before the first administration without using blood products or hematopoietic stimulating